OCRX Ocera Therapeutics, Inc.

0.65
+0  (0%)
Previous Close 0.65
Open 0.65
Price To book 0.79
Market Cap 14.93M
Shares 23,143,000
Volume 706,214
Short Ratio 0.51
Av. Daily Volume 1,121,600

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released January 30, 2017 - primary endpoint not met.
OCR-002 (IV)
Hepatic encephalopathy
Phase 2a trial to be initiated 1H 2017.
OCR-002
Cirrhosis

Latest News

  1. Lifshitz & Miller LLP Announces Investigation of Centrue Financial Corporation, Motorola Solutions, Inc., Natus Medical Incorporated, Northern Dynasty Minerals Ltd., Ocera Therapeutics, Inc., Psychemedics Corporation, RH and Stemline Therap
  2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ocera Therapeutics, Inc.
  3. Ocera Therapeutics downgraded by JMP Securities
  4. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  5. Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy
  6. ETFs with exposure to Ocera Therapeutics, Inc. : January 19, 2017
  7. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events
  8. Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
  9. Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis
  10. ETFs with exposure to Ocera Therapeutics, Inc. : December 29, 2016
  11. Ocera Therapeutics (OCRX) Catches Eye: Stock Jumps 6.8%
  12. How Cenveo, Inc. (CVO) Stacks Up Against Its Peers
  13. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. Ocera Completes Enrollment of STOP-HE, a Phase 2b Study of OCR-002 in Hospitalized Patients with Hepatic Encephalopathy
  15. OCERA THERAPEUTICS, INC. Financials
  16. ETF’s with exposure to Ocera Therapeutics, Inc. : November 4, 2016
  17. Ocera Therapeutics, Inc. :OCRX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 3, 2016
  18. Ocera Therapeutics Reports Third Quarter 2016 Financial Results and Company Update
  19. OCERA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  20. Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of Directors